

DISCUVA LIMITED

(the “Company”)

PRIVATE COMPANY LIMITED BY SHARES

**RESOLUTION TO WHICH CHAPTER 3 OF PART 3
OF THE COMPANIES ACT 2006 APPLIES**

The following resolutions were passed in writing pursuant to Chapter 2 of Part 13 of the Companies Act 2006, resolutions 1 and 3 as ordinary resolutions and resolution 2 as a special resolution on 12 March 2024:

ORDINARY RESOLUTION

1. **THAT**, the full amount standing to the credit of the capital contribution reserves of the Company be and is hereby capitalised and appropriated as capital to the sole shareholder of the Company, being Summit Therapeutics Limited, and that the directors be and are hereby authorised to apply such sum in paying up the full 1,458,507,000 ordinary shares of £0.001 each in the capital of the Company and to allot and issue such new shares, credited as fully paid up, to the sole shareholder of the Company.
2. **THAT**, subject to the passing of resolutions 1 and 3, a final dividend of an aggregate amount of £2,633,809 be declared to the sole member of the Company, Summit Therapeutics Limited.

SPECIAL RESOLUTION

3. **THAT**, subject to the passing of resolution 1 above, the share capital of the Company be reduced by cancelling 1,458,507,000 fully paid ordinary shares of £0.001 each in the capital of the Company.

Ankur Dhingra
Ankur Dhingra (Mar 6, 2024 22:16 PST)
Director

Date 12 March 2024
.....